As of November 14, 2026, Helus Pharma Inc. is a publicly traded company (Nasdaq: HELP). The largest holder reporting an active stake on Schedule 13D is Paul Glavine, the executive officer and a director, at 5.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Eric So, the executive officer and a director (5.8%) (Schedule 13D, September 9, 2026).
Is this your company?
About to sign with, pay or invest in Helus Pharma Inc.? See the free Snapshot first.
Free to see. No signup.
Is Helus Pharma Inc. a real, registered company?
- Helus Pharma Inc. files with the SEC under CIK 1833141 (its SEC filings).
- Its shares are listed under the ticker HELP on Nasdaq (SEC company record).
- Incorporated in A1, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CYBIN INC. in our court records and SEC 8-K records (as of 2026-11-14).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Adage Capital (filed 2026-11-12).
Who are Helus Pharma Inc.'s owners and officers?
Helus Pharma Inc.: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-12).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Executive Officer, Director (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Executive Officer (Form D, 2026-09-01)
- : Director (Form D, 2026-09-01)
- : Director (Form D, 2026-09-01)
- : Director (Form D, 2026-09-01)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-12 | Millennium Management LLC | 1.4% |
| Schedule 13G/A, 2026-11-12 | Adage Capital Management, L.P. | 7.48% |
| Schedule 13D, 2026-09-09 | Glavine Paul | 5.8% |
| Schedule 13D, 2026-09-09 | So Eric H. L. | 5.8% |
| Schedule 13G/A, 2026-08-14 | Sirenia Capital Management LP | 4.8% |
| Schedule 13G, 2026-08-12 | Adage Capital Management, L.P. | 5.29% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 7.2% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 1.4% |
| Schedule 13G/A, 2026-04-22 | Millennium Management LLC | 5.7% |
| Schedule 13G, 2026-04-10 | Millennium Management LLC | 5% |
| Schedule 13G, 2026-03-26 | Millennium Management LLC | 4.8% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 0% |
Questions about who owns Helus Pharma Inc.
Who owns Helus Pharma Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Helus Pharma Inc.: Adage Capital Management, L.P. (7.48%, Schedule 13G/A, filed 2026-11-12), Glavine Paul (5.8%, Schedule 13D, filed 2026-09-09) and So Eric H. L. (5.8%, Schedule 13D, filed 2026-09-09).
Who are the largest shareholders of Helus Pharma Inc.?
By the share each holder's latest filing reports, the largest holders of Helus Pharma Inc. on this page are Adage Capital Management, L.P. (7.48%), Glavine Paul (5.8%) and So Eric H. L. (5.8%).
When did Adage Capital Management, L.P. buy into Helus Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Adage Capital Management, L.P. on this page is the Schedule 13G, filed 2026-08-12, reporting 5.29%; its latest, Schedule 13G/A filed 2026-11-12, reports 7.48%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Helus Pharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Helus Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Helus Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
26 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Helus Pharma Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 4,766,630 shares (22.1% of shares outstanding), 4,713,014 held directly and 53,616 indirectly (Form 4, 2026-10-01).
- , the chief growth officer and a director: 4,750,191 shares (22.0% of shares outstanding) (Form 4, 2026-10-01).
- , a director: 227,822 shares (1.1% of shares outstanding), 3,490 held directly and 224,332 indirectly (Form 3, 2026-10-26).
- , the chief executive: 168,568 shares (0.78% of shares outstanding) (Form 4, 2026-09-21).
- , a director: 161,263 shares (0.75% of shares outstanding), held indirectly through Held by Greywolf Management Services Inc. (Form 3, 2026-10-23).
Shares outstanding: 21,601,208 as of 2025-03-31, from the company's latest SEC cover page.
How much has Helus Pharma Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-09-01 | $0 | $262K |
| Form D, 2026-08-19 | $0 | not stated |
| Form D, 2026-08-19 | $0 | not stated |
| Form D, 2026-07-16 | $0 | $512K |
| Form D, 2026-07-16 | $0 | not stated |
| Form D, 2026-03-23 | $0 | not stated |
| Form D, 2026-01-12 | $0 | $114K |
| Form D, 2025-11-26 | $0 | $289K |
Keep reading
More on Helus Pharma Inc. and the records around it.
Helus Pharma Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), Design Therapeutics, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/helus-pharma